NYRADA INC. - Announcements

7.41%

29.0¢

Market Cap $69.25M

Healthcare Biotechnology

Nyrada Inc is an Australia-based drug development company. The Company focuses on... Nyrada Inc is an Australia-based drug development company. The Company focuses on development of small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. Its drug development programs include a proprotein convertase subtilisin/kexin type nine (PCSK9) inhibitor for the treatment of high blood low-density lipoprotein (LDL)-cholesterol levels in patients poorly responsive to or unable to take statin drugs. It develops a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury. The Company also develops a drug to treat pain associated with peripheral nerve damage and autoimmune diseases such as psoriasis.More

Recce Pharmaceuticals (ASX:RCE) eyes US Defence grants with early data for R327 on burn wounds

Announcements

Filter Results

All Price Sensitive Only

NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	26/10/22	554.93KB	Share
NYR	2022 AGM Letter to Shareholders and Proxy		18/10/22	709.98KB	Share
NYR	2022 AGM Notice of Meeting and Proxy		18/10/22	794.17KB	Share
NYR	Efficacy Study Published in Journal of Lipid Research		10/10/22	233.01KB	Share
NYR	Presentation to ShareCafe Hidden Gems Webinar		29/09/22	1.27MB	Share
NYR	Presentation to E&P Small Caps Health Care Conference		05/09/22	2.11MB	Share
NYR	Nyrada Reports Full Year FY2022 Results		29/08/22	333.75KB	Share
NYR	Annual Report to June 30 2022		29/08/22	2.52MB	Share
NYR	Preliminary Final Report	PRICE SENSITIVE	29/08/22	205.27KB	Share
NYR	Appendix 4G and Corporate Governance Statement		29/08/22	3.07MB	Share
NYR	Nyrada Board Changes		02/08/22	206.09KB	Share
NYR	Initial Director's Interest Notice - GM		02/08/22	146.46KB	Share
NYR	Final Director's Interest Notice - PM		02/08/22	3.27KB	Share
NYR	Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	26/07/22	434.69KB	Share
NYR	Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis	PRICE SENSITIVE	20/07/22	207.35KB	Share
NYR	Cholesterol-Lowering Program Update	PRICE SENSITIVE	29/06/22	215.89KB	Share
NYR	Corporate Presentation	PRICE SENSITIVE	07/06/22	1.82MB	Share
NYR	Brain Injury Program Target Unveiled and Phase I Update	PRICE SENSITIVE	06/06/22	310.7KB	Share
NYR	European Patent to be Granted for Cholesterol-Lowering Drug	PRICE SENSITIVE	17/05/22	223.96KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	19/04/22	422.49KB	Share
NYR	Investor Roadshow Presentation		30/03/22	1.9MB	Share
NYR	New Drug Offers Potential Oral Treatment for Concussion	PRICE SENSITIVE	29/03/22	301.04KB	Share
NYR	Presentation to Meet the CEO Life Sciences Edition		02/03/22	1.73MB	Share
NYR	Nyrada Half Year Results FY2022	PRICE SENSITIVE	25/02/22	283.42KB	Share
NYR	Appendix 4D and Half Year Report to 31 December 2021	PRICE SENSITIVE	25/02/22	573.91KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	21/01/22	579.1KB	Share
NYR	Application for quotation of securities - NYR		17/01/22	24.32KB	Share
NYR	Change of Director's Interest Notice - ID		17/01/22	5.79KB	Share
NYR	Change of Director's Interest Notice - MF		17/01/22	6.03KB	Share
NYR	Change of Director's Interest Notice - RW		17/01/22	5.95KB	Share
NYR	Change of Director's Interest Notice - JM		17/01/22	4.85KB	Share
NYR	Change of Director's Interest Notice - CC		17/01/22	6.02KB	Share
NYR	Change of Director's Interest Notice - PM		17/01/22	6.13KB	Share
NYR	Nyrada Receives A$1.3M R&D Tax Incentive Rebate	PRICE SENSITIVE	12/01/22	218.39KB	Share
NYR	Brain Injury Program Update and Pathway to Phase I		04/01/22	246.72KB	Share
NYR	Cholesterol-Lowering Program Pathway to Phase I	PRICE SENSITIVE	22/12/21	201.38KB	Share
NYR	Release of Securities from Escrow		10/12/21	199KB	Share
NYR	Nyrada Annual General Meeting Results		19/11/21	237.02KB	Share
NYR	Annual General Meeting Presentation		19/11/21	1.94MB	Share
NYR	Nyrada AGM 2021 Chairman's Address		19/11/21	259.46KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	26/10/21	488.88KB	Share
NYR	2021 AGM Notice of Meeting and Proxy		19/10/21	3.52MB	Share
NYR	2021 AGM Letter to Shareholders and Proxy		19/10/21	1.78MB	Share
NYR	Presentation to ASX Small and Mid-Cap Conference		13/09/21	1.12MB	Share
NYR	Updated Share Trading Policy		03/09/21	344.17KB	Share
NYR	Nyrada Reports Full Year FY2021 Results	PRICE SENSITIVE	30/08/21	254.9KB	Share
NYR	Annual Report to 30 June 2021		30/08/21	3.52MB	Share
NYR	Preliminary Final Report	PRICE SENSITIVE	30/08/21	226.37KB	Share
NYR	Appendix 4G and Corporate Governance Statement		30/08/21	870.19KB	Share
NYR	NYX-PCSK9i In Vivo Study Exploratory Analysis Results		13/08/21	491.21KB	Share
NYR	Nyrada Announces US Patent Grant for PCSK9 Inhibitor	PRICE SENSITIVE	30/07/21	224.97KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	27/07/21	545.06KB	Share
NYR	Change of Director's Interest Notice - CC		30/06/21	6.15KB	Share
NYR	Change of Director's Interest Notice - ID		30/06/21	5.11KB	Share
NYR	Change of Director's Interest Notice - RW		30/06/21	6.05KB	Share
NYR	Change of Director's Interest Notice - MF		30/06/21	6.12KB	Share
NYR	Change of Director's Interest Notice - PM		30/06/21	5.9KB	Share
NYR	Change of Director's Interest Notice - JM		30/06/21	4.95KB	Share
NYR	Change in substantial holding		30/06/21	219.72KB	Share
NYR	Change in substantial holding		30/06/21	222.58KB	Share
NYR	Cleansing Statement		29/06/21	230.73KB	Share
NYR	Confirmation of Capital Structure, CDIs on Issue		29/06/21	227.68KB	Share
NYR	Notification regarding unquoted securities - NYR		29/06/21	26.01KB	Share
NYR	Application for quotation of securities - NYR		29/06/21	25.09KB	Share
NYR	Application for quotation of securities - NYR		29/06/21	25.04KB	Share
NYR	NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction	PRICE SENSITIVE	29/06/21	405.5KB	Share
NYR	Results of Meeting		16/06/21	274.05KB	Share
NYR	Improved Drug Candidate Selected for WRAIR Studies	PRICE SENSITIVE	15/06/21	290.19KB	Share
NYR	Notice of Extraordinary General Meeting/Proxy Form		11/05/21	3.15MB	Share
NYR	Nyrada Receives A$1.0M R&D Tax Incentive Rebate	PRICE SENSITIVE	06/05/21	191.19KB	Share
NYR	NYR Announces New Potent Cholesterol-Lowering Candidates	PRICE SENSITIVE	05/05/21	320.6KB	Share
NYR	Change of Registered Office and Principal Place of Business		26/04/21	192.29KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	20/04/21	514.32KB	Share
NYR	Change in substantial holding		30/03/21	183.96KB	Share
NYR	Ceasing to be a substantial holder		30/03/21	198.8KB	Share
NYR	Change in substantial holding		30/03/21	211.57KB	Share
NYR	Cleansing Statement		30/03/21	201.91KB	Share
NYR	Appendix 2A		30/03/21	279.49KB	Share
NYR	Change in substantial holding		25/03/21	198.33KB	Share
NYR	Proposed issue of Securities - NYR		22/03/21	37.18KB	Share
NYR	Nyrada Receives Firm Commitments to Raise A$11 Million	PRICE SENSITIVE	22/03/21	231.78KB	Share
NYR	Nyrada Investor Presentation		18/03/21	1.52MB	Share
NYR	Trading Halt	PRICE SENSITIVE	17/03/21	236.75KB	Share
NYR	Change of Director's Interest Notice - JM		05/03/21	376.31KB	Share
NYR	Nyrada Newsletter February 2021		02/03/21	269.95KB	Share
NYR	Appendix 3G		24/02/21	283.77KB	Share
NYR	Change of Director's Interest Notice - MF		24/02/21	272.16KB	Share
NYR	Investor Presentation to Finance News Network CEO Showcase		23/02/21	1.57MB	Share
NYR	Nyrada Reports Half Year FY2021 Results	PRICE SENSITIVE	22/02/21	239.67KB	Share
NYR	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	22/02/21	700.02KB	Share
NYR	Lapsing of balance of Unlisted SAB Options		16/02/21	212.8KB	Share
NYR	Cleansing Statement		16/02/21	201.22KB	Share
NYR	Appendix 2A		16/02/21	280KB	Share
NYR	NYR Secures Collaboration with Walter Reed and UNSW	PRICE SENSITIVE	01/02/21	326.73KB	Share
NYR	Trading Halt	PRICE SENSITIVE	29/01/21	251.74KB	Share
NYR	Nyrada Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	28/01/21	543.49KB	Share
NYR	Nyrada Reports Further Results from Cholesterol Study		25/01/21	423.43KB	Share
NYR	Unlisted Scientific Advisory Board Options Expiry 15 Feb 21		22/01/21	184.6KB	Share
NYR	Change of Director's Interest Notice - ID		18/01/21	454.4KB	Share
NYR	Appendix 3G		18/01/21	274.57KB	Share

NYR Quarterly Activities Report and Appendix 4C
26/10/22	PRICE SENSITIVE	554.93KB	Share
NYR 2022 AGM Letter to Shareholders and Proxy
18/10/22		709.98KB	Share
NYR 2022 AGM Notice of Meeting and Proxy
18/10/22		794.17KB	Share
NYR Efficacy Study Published in Journal of Lipid Research
10/10/22		233.01KB	Share
NYR Presentation to ShareCafe Hidden Gems Webinar
29/09/22		1.27MB	Share
NYR Presentation to E&P Small Caps Health Care Conference
05/09/22		2.11MB	Share
NYR Nyrada Reports Full Year FY2022 Results
29/08/22		333.75KB	Share
NYR Annual Report to June 30 2022
29/08/22		2.52MB	Share
NYR Preliminary Final Report
29/08/22	PRICE SENSITIVE	205.27KB	Share
NYR Appendix 4G and Corporate Governance Statement
29/08/22		3.07MB	Share
NYR Nyrada Board Changes
02/08/22		206.09KB	Share
NYR Initial Director's Interest Notice - GM
02/08/22		146.46KB	Share
NYR Final Director's Interest Notice - PM
02/08/22		3.27KB	Share
NYR Quarterly Activities Report and Appendix 4C
26/07/22	PRICE SENSITIVE	434.69KB	Share
NYR Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis
20/07/22	PRICE SENSITIVE	207.35KB	Share
NYR Cholesterol-Lowering Program Update
29/06/22	PRICE SENSITIVE	215.89KB	Share
NYR Corporate Presentation
07/06/22	PRICE SENSITIVE	1.82MB	Share
NYR Brain Injury Program Target Unveiled and Phase I Update
06/06/22	PRICE SENSITIVE	310.7KB	Share
NYR European Patent to be Granted for Cholesterol-Lowering Drug
17/05/22	PRICE SENSITIVE	223.96KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
19/04/22	PRICE SENSITIVE	422.49KB	Share
NYR Investor Roadshow Presentation
30/03/22		1.9MB	Share
NYR New Drug Offers Potential Oral Treatment for Concussion
29/03/22	PRICE SENSITIVE	301.04KB	Share
NYR Presentation to Meet the CEO Life Sciences Edition
02/03/22		1.73MB	Share
NYR Nyrada Half Year Results FY2022
25/02/22	PRICE SENSITIVE	283.42KB	Share
NYR Appendix 4D and Half Year Report to 31 December 2021
25/02/22	PRICE SENSITIVE	573.91KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
21/01/22	PRICE SENSITIVE	579.1KB	Share
NYR Application for quotation of securities - NYR
17/01/22		24.32KB	Share
NYR Change of Director's Interest Notice - ID
17/01/22		5.79KB	Share
NYR Change of Director's Interest Notice - MF
17/01/22		6.03KB	Share
NYR Change of Director's Interest Notice - RW
17/01/22		5.95KB	Share
NYR Change of Director's Interest Notice - JM
17/01/22		4.85KB	Share
NYR Change of Director's Interest Notice - CC
17/01/22		6.02KB	Share
NYR Change of Director's Interest Notice - PM
17/01/22		6.13KB	Share
NYR Nyrada Receives A$1.3M R&D Tax Incentive Rebate
12/01/22	PRICE SENSITIVE	218.39KB	Share
NYR Brain Injury Program Update and Pathway to Phase I
04/01/22		246.72KB	Share
NYR Cholesterol-Lowering Program Pathway to Phase I
22/12/21	PRICE SENSITIVE	201.38KB	Share
NYR Release of Securities from Escrow
10/12/21		199KB	Share
NYR Nyrada Annual General Meeting Results
19/11/21		237.02KB	Share
NYR Annual General Meeting Presentation
19/11/21		1.94MB	Share
NYR Nyrada AGM 2021 Chairman's Address
19/11/21		259.46KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
26/10/21	PRICE SENSITIVE	488.88KB	Share
NYR 2021 AGM Notice of Meeting and Proxy
19/10/21		3.52MB	Share
NYR 2021 AGM Letter to Shareholders and Proxy
19/10/21		1.78MB	Share
NYR Presentation to ASX Small and Mid-Cap Conference
13/09/21		1.12MB	Share
NYR Updated Share Trading Policy
03/09/21		344.17KB	Share
NYR Nyrada Reports Full Year FY2021 Results
30/08/21	PRICE SENSITIVE	254.9KB	Share
NYR Annual Report to 30 June 2021
30/08/21		3.52MB	Share
NYR Preliminary Final Report
30/08/21	PRICE SENSITIVE	226.37KB	Share
NYR Appendix 4G and Corporate Governance Statement
30/08/21		870.19KB	Share
NYR NYX-PCSK9i In Vivo Study Exploratory Analysis Results
13/08/21		491.21KB	Share
NYR Nyrada Announces US Patent Grant for PCSK9 Inhibitor
30/07/21	PRICE SENSITIVE	224.97KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
27/07/21	PRICE SENSITIVE	545.06KB	Share
NYR Change of Director's Interest Notice - CC
30/06/21		6.15KB	Share
NYR Change of Director's Interest Notice - ID
30/06/21		5.11KB	Share
NYR Change of Director's Interest Notice - RW
30/06/21		6.05KB	Share
NYR Change of Director's Interest Notice - MF
30/06/21		6.12KB	Share
NYR Change of Director's Interest Notice - PM
30/06/21		5.9KB	Share
NYR Change of Director's Interest Notice - JM
30/06/21		4.95KB	Share
NYR Change in substantial holding
30/06/21		219.72KB	Share
NYR Change in substantial holding
30/06/21		222.58KB	Share
NYR Cleansing Statement
29/06/21		230.73KB	Share
NYR Confirmation of Capital Structure, CDIs on Issue
29/06/21		227.68KB	Share
NYR Notification regarding unquoted securities - NYR
29/06/21		26.01KB	Share
NYR Application for quotation of securities - NYR
29/06/21		25.09KB	Share
NYR Application for quotation of securities - NYR
29/06/21		25.04KB	Share
NYR NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction
29/06/21	PRICE SENSITIVE	405.5KB	Share
NYR Results of Meeting
16/06/21		274.05KB	Share
NYR Improved Drug Candidate Selected for WRAIR Studies
15/06/21	PRICE SENSITIVE	290.19KB	Share
NYR Notice of Extraordinary General Meeting/Proxy Form
11/05/21		3.15MB	Share
NYR Nyrada Receives A$1.0M R&D Tax Incentive Rebate
06/05/21	PRICE SENSITIVE	191.19KB	Share
NYR NYR Announces New Potent Cholesterol-Lowering Candidates
05/05/21	PRICE SENSITIVE	320.6KB	Share
NYR Change of Registered Office and Principal Place of Business
26/04/21		192.29KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
20/04/21	PRICE SENSITIVE	514.32KB	Share
NYR Change in substantial holding
30/03/21		183.96KB	Share
NYR Ceasing to be a substantial holder
30/03/21		198.8KB	Share
NYR Change in substantial holding
30/03/21		211.57KB	Share
NYR Cleansing Statement
30/03/21		201.91KB	Share
NYR Appendix 2A
30/03/21		279.49KB	Share
NYR Change in substantial holding
25/03/21		198.33KB	Share
NYR Proposed issue of Securities - NYR
22/03/21		37.18KB	Share
NYR Nyrada Receives Firm Commitments to Raise A$11 Million
22/03/21	PRICE SENSITIVE	231.78KB	Share
NYR Nyrada Investor Presentation
18/03/21		1.52MB	Share
NYR Trading Halt
17/03/21	PRICE SENSITIVE	236.75KB	Share
NYR Change of Director's Interest Notice - JM
05/03/21		376.31KB	Share
NYR Nyrada Newsletter February 2021
02/03/21		269.95KB	Share
NYR Appendix 3G
24/02/21		283.77KB	Share
NYR Change of Director's Interest Notice - MF
24/02/21		272.16KB	Share
NYR Investor Presentation to Finance News Network CEO Showcase
23/02/21		1.57MB	Share
NYR Nyrada Reports Half Year FY2021 Results
22/02/21	PRICE SENSITIVE	239.67KB	Share
NYR Appendix 4D and Half Year Accounts
22/02/21	PRICE SENSITIVE	700.02KB	Share
NYR Lapsing of balance of Unlisted SAB Options
16/02/21		212.8KB	Share
NYR Cleansing Statement
16/02/21		201.22KB	Share
NYR Appendix 2A
16/02/21		280KB	Share
NYR NYR Secures Collaboration with Walter Reed and UNSW
01/02/21	PRICE SENSITIVE	326.73KB	Share
NYR Trading Halt
29/01/21	PRICE SENSITIVE	251.74KB	Share
NYR Nyrada Quarterly Activities Report & Appendix 4C
28/01/21	PRICE SENSITIVE	543.49KB	Share
NYR Nyrada Reports Further Results from Cholesterol Study
25/01/21		423.43KB	Share
NYR Unlisted Scientific Advisory Board Options Expiry 15 Feb 21
22/01/21		184.6KB	Share
NYR Change of Director's Interest Notice - ID
18/01/21		454.4KB	Share
NYR Appendix 3G
18/01/21		274.57KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 29.0¢		Change 0.020(7.41%)		Mkt cap ! $69.25M

Open	High	Low	Value	Volume
27.0¢	29.0¢	27.0¢	$125.1K	445.1K

Buyers (Bids)

No.	Vol.	Price($)
2	19172	29.0¢

Sellers (Offers)

Price($)	Vol.	No.
29.5¢	7200	1

View Market Depth

No.	Vol.	Price($)
1	2000	0.290
2	15000	0.285
2	32000	0.280
1	36363	0.275
1	67735	0.270

Price($)	Vol.	No.
0.295	7200	1
0.300	20000	1
0.310	15075	2
0.320	178150	4
0.340	69332	1

Last trade - 16.10pm 05/09/2025 (20 minute delay)

NYR (ASX) Chart

NYRADA INC. - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories